Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Novo Nordisk is preparing to launch Wegovy in India, where millions of people are battling obesity and demand for the weight-loss drug is expected to be massive. The drug will be launched in ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the d… ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T2D) and Wegovy for obesity. Ozempic and Wegovy include the same ...

During this time, compounded versions became a more accessible option. Now, brand-name GLP-1 injections of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are available again.

Compounded glucagon-like peptide-1 (GLP-1) medications gained popularity during shortages of FDA-approved brand-name GLP-1s. Now that the shortages have resolved, compounded GLP-1s are largely being ...

During this time, compounded versions became a more accessible option. Now, brand-name GLP-1 injections of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are available again.

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make the process of switching from a compounded GLP-1 to a brand-name GLP-1 ...